Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIX001
- Development stage
- Phase 1
- Lead developer
- Neobiosis
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Topical
01
Overview
VIX001 is a proprietary biological product derived from purified amniotic fluid. It is being developed for the treatment of neurological and inflammatory conditions, with a primary focus on post-acute COVID-19 syndrome (PACS) patients experiencing cognitive impairment and neurological symptoms. The drug has also been explored in case studies for wound healing in diabetic ulcers, severe back pain due to spondylitis, and pyoderma gangrenosum—demonstrating rapid reduction in pain and inflammation as well as accelerated tissue regeneration. Its mechanism of action is not fully elucidated but may involve extracellular vesicles present in amniotic fluid that mediate anti-inflammatory effects and promote tissue repair. VIX001 is administered intravenously or topically depending on the indication. The developer and active organization behind VIX001 is NEOBIOSIS.
- Other names
- ViX001ViX-001ViX 001
Beyond the preview
Go deeper on VIX001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIX001.